# US 2017/0283479 A1 · Lipidated amide-based insulin prodrugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283479 A1
- Document ID: US20170283479A1
- Status: Published application
- Kind: A1
- Application number: 15/513,762
- Filed: 2015-09-23
- Published: 2017-10-05
- Earliest claimed: 2014-09-24
- Assignees: Indiana University Research and Technology Corporation
- Applicants: Indiana University Research and Technology Corporation
- Inventors: Richard D. DIMARCHI; Binbin KOU; Fa ZHANG; John P. MAYER
- Web page: https://patentgrep.com/patent/US20170283479A1

## CPC

- C07K 14/62: Insulins
- A61K 38/28: Insulins
- A61K 47/54: the modifying agent being an organic compound
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61K 47/6911: {the form being a liposome}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 47/00: Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by an amide bond linkage of a dipeptide prodrug element. The prodrugs disclosed herein have extended half-lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.

## Claims

### Claim 1

An insulin prodrug comprising the structure:
A-B-C-Q;
wherein Q is an insulin peptide;
A is an amino acid comprising a side chain covalently linked via a spacer to a moiety that irreversibly binds to a plasma protein, wherein said spacer comprises one or two charged amino acids;
B is an N-alkylated amino acid; and
C is X70 or X70X71, wherein X70 and X71 are amino acids with a side chain independently selected from the group consisting of H, (C1-C4 alkyl)COOH, (C1-C4 alkyl)SO3H, (C1-C4 alkyl)NH2, (C1-C4 alkyl)NHC(NH2+)NH2, wherein A-B-C is linked to Q through an amide bond via an aliphatic amino group of Q, said aliphatic amino group selected from the alpha amino group on the N-terminal amino acid of the A chain or the B chain, or an aliphatic amino group on a side chain of an B3, B28 or B29 amino acid of Q.

### Claim 2 (depends on 1)

The prodrug of claim 1, wherein
A is an amino acid comprising a (C1-C8 alkyl)NH2 side chain, and said moiety is a C16-C30 acyl group or a C16-C30 alkyl group, wherein the linkage between the side chain of A and the acyl or alkyl group is via said spacer;
B is an amino acid N-alkylated with C1-C18 alkyl, C3-C18 alkenyl, (C1-C4 alkyl)(C4-C6 cycloalkyl), (C1-C4 alkyl)(C3-C5 heterocyclic), or (C1-C4 alkyl)(C6-C10 aryl); and
X70 and X71 are amino acids independently selected from the group consisting of glycine, aspartic acid, glutamic acid, cysteic acid, arginine, and lysine.

### Claim at position 3

3-4. (canceled)

### Claim 5

An insulin prodrug comprising the structure:
M1-A-B-C-Q;
wherein Q is an insulin peptide;
A is an amino acid comprising a side chain covalently linked to a moiety that irreversibly binds to a plasma protein, optionally wherein said moiety is linked to the side chain of A via a spacer, said spacer comprising one or two charged amino acids;
B is an N-alkylated amino acid;
C is an amide bond, X70 or X70X71; and
M1 is a serum enzyme cleavable moiety linked to A via the N-terminal amine of A, wherein
X70 and X71 are amino acids with a side chain independently selected from the group consisting of H, (C1-C4 alkyl)COOH, (C1-C4 alkyl)SO3H, (C1-C4 alkyl)NH2, (C1-C4 alkyl)NHC(NH2+)NH2, further wherein A-B-C is linked to Q through an amide bond via an aliphatic amino group of Q, said aliphatic amino group selected from the alpha amino group on the N-terminal amino acid of the A chain or the B chain, or an aliphatic amino group on a side chain of an B3, B28 or B29 amino acid of Q.

### Claim 6

(canceled)

### Claim 7 (depends on 5)

The prodrug of claim 5, wherein the serum enzyme cleavable peptide moiety is a dipeptide have the sequence Z-proline, or Z-alanine wherein Z is selected from the group consisting of Glycine, Alanine, Valine, Leucine, Isoleucine, Proline, Phenylalanine, Tyrosine, Tryptophan, Serine, Threonine, Methionine, Asparagine, Glutamine, Lysine, Arginine, Histidine, Aspartic acid, and Glutamic acid.

### Claim 8 (depends on 7)

The prodrug of claim 7 wherein the serum enzyme cleavable peptide moiety is Arg-Pro, Lys-Pro or Glu-Pro.

### Claim at position 8

9-10. (canceled)

### Claim 11 (depends on 5)

The prodrug of claim 5, wherein A-B-C comprises the structure:
wherein
R1 is C18-C30 alkyl, (C1-C6 alkyl)NH—R9; or (C1-C6 alkyl)NH—S1—R9;
R2 is H or C1-C6 alkyl:
R3 is selected from the group consisting of C2-C4 alkyl, C3-C8 alkenyl, (C0-C4 alkyl)(C4-C6 cycloalkyl), (C0-C4 alkyl)(C3-C5 heterocyclic), (C0-C4 alkyl)(C6-C10 aryl) or R4 and R3 together with the atoms to which they are attached form a 4, 5 or 6 member heterocyclic ring;
R4, and R8 are independently selected from the group consisting of H, C1-C18 alkyl, C2-C18 alkenyl, (C1-C18 alkyl)OH, (C1-C18 alkyl)SH, (C2-C3 alkyl)SCH3, (C1-C4 alkyl)CONH2, (C1-C4 alkyl)COOH, (C1-C4 alkyl)NH2, (C1-C4 alkyl)NHC(NH2+)NH2, (C0-C4 alkyl)(C3-C6 cycloalkyl), (C0-C4 alkyl)(C2-C5 heterocyclic), (C0-C4 alkyl)(C6-C10 aryl)R7, (C1-C4 alkyl)(C3-C9 heteroaryl), and C1-C12 alkyl(W1)C1-C12 alkyl, wherein W1 is a heteroatom selected from the group consisting of N, S and O, or R4 and R8 together with the atoms to which they are attached form a C3-C6 cycloalkyl;
R10, R11, R12, and R13 are independently selected from the group consisting of H, CH3, (C1-C4 alkyl)COOH, (C1-C4 alkyl)NH2, (C1-C4 alkyl)NHC(NH2+)NH2 and CH2(C3—N2 heterocyclic);
R5 is NHR6 or OH;
R6 is H, or C1-C8 alkyl;
R7 is selected from the group consisting of H, OH, C1-C18 alkyl, C2-C18 alkenyl, (C0-C4 alkyl)NH2, and (C0-C4 alkyl)OH;
R9 is selected from the group consisting of C18-C30 acyl; and
S1 is a bond or a spacer consisting of one to six amino acids, wherein said spacer comprises one or more charged amino acids selected from the group consisting of aspartic acid, glutamic acid, cysteic acid, arginine and lysine.

### Claim 12

(canceled)

### Claim 13 (depends on 11)

The prodrug of claim 11, wherein A-B-C comprises the structure:
wherein
R1 is (CH2)4—S1—NHR9;
R3 is C3-C4 alkyl;
R4, R1, and R13 are each H
R5 is NH2;
R8 is H or C1-C8 alkyl;
R9 is C18-C30 acyl;
R10 and R12 are independently selected from the group consisting of (C1-C4 alkyl)COOH, (C1-C4 alkyl)NH2 and (C1-C4 alkyl)NHC(NH2+)NH2; and
S1 is a spacer consisting of one or two charged amino acids selected from the group consisting of aspartic acid, glutamic acid, cysteic acid, arginine and lysine.

### Claim 14 (depends on 13)

The prodrug of claim 13, wherein
R1 is selected from the group consisting of (CH2)4NHCO(CH2)17CH3 and (CH2)4NHCO(CH2)19CH3.

### Claim 15 (depends on 1)

The prodrug of claim 1 wherein said insulin peptide comprises an A chain sequence of GIVEQCCX8SICSLYQLENYCX21 (SEQ ID NO: 3) and a B chain sequence of R22-HLCGSHLVEALYLVCGERGFX45 (SEQ ID NO: 15),
wherein
said B chain is linked to said A chain through disulfide linkages;
R22 is a bond, or a 1 to 4 amino acid sequence selected from the group consisting of a FVNQ (SEQ ID NO: 12), FVKQ (SEQ ID NO: 8), VNQ, NQ and Q;
X8 is selected from the group consisting of threonine and histidine;
X21 is selected from the group consisting of asparagine, lysine, glycine, alanine; and
X45 is histidine, tyrosine or phenylalanine.

### Claim at position 14

16-18. (canceled)

### Claim 19 (depends on 15)

The prodrug of claim 15 wherein said A chain comprises a sequence GIVEQCCTSICSLYQLENYCN-R44 (SEQ ID NO: 1) and said B chain comprises a sequence selected from the group consisting of FVNQHLCGSHLVEALYLVCGERGFFYTPKT (SEQ ID NO: 2) FVNQHLCGSHLVEALYLVCGERGFFYTKPT (SEQ ID NO: 9) FVNQHLCGSHLVEALYLVCGERGFFYTDKT (SEQ ID NO: 5) and FVKQHLCGSHLVEALYLVCGERGFFYTEKT (SEQ ID NO: 6).

### Claim 20

An insulin prodrug comprising the structure:
A-B-C-Q;
wherein Q is an insulin peptide; and
A-B-C comprises the structure:
wherein
A-B-C is linked to Q through an amide bond via the N-terminal amino acid of the A chain or the B chain, or an aliphatic amino group on a side chain of an B3, B28 or B29 amino acid of Q,
R1 is selected from the group consisting of H, (C1-C4 alkyl)O—S1—R9, (C1-C4 alkyl)S—S1—R9, (C1-C4 alkyl)CONH—S1—R9, (C1-C4 alkyl)COO—S1—R9, (C1-C6 alkyl)NH—S1—R9, (C1-C6 alkyl)NHR9 and (C0-C4 alkyl)(C6-C10 aryl)-S1—R9;
R2 and R8 are independently selected from the group consisting of H, C1-C8 alkyl, C2-C8 alkenyl, (C1-C4 alkyl)OH, (C1-C4 alkyl)SH, (C2-C3 alkyl)SCH3, (C1-C4 alkyl)CONHH, (C1-C4 alkyl)COOH, (C1-C4 alkyl)NHH, (C1-C4 alkyl)NHC(NH2+)NH2, (C0-C4 alkyl)(C3-C6 cycloalkyl), (C0-C4 alkyl)(C2-C5 heterocyclic), (C0-C4 alkyl)(C6-C10 aryl)R7, (C1-C4 alkyl)(C3-C9 heteroaryl), and C1-C12 alkyl(W1)C1-C12 alkyl, wherein W1 is a heteroatom selected from the group consisting of N, S and O, or R1 and R2 together with the atoms to which they are attached form a C3-C12 cycloalkyl or aryl;
R3 is C1-C18 alkyl, C3-C8 alkenyl, (C1-C4 alkyl)(C4-C6 cycloalkyl), (C1-C4 alkyl)(C3-C5 heterocyclic), (C1-C4 alkyl)(C6-C10 aryl) or R4 and R3 together with the atoms to which they are attached form a 4, 5 or 6 member heterocyclic ring;
R4 is H, C1-C18 alkyl, (C1-C6 alkyl)NHR9 or C1-C6 alkyl)NH—S1—R9,
R5 is OH, or NHR6;
R6 is H, C1-C8 alkyl;
R7 is selected from the group consisting of H, OH and OR9;
R9 is selected from the group consisting of C16-C30 acyl, and C16-C30 alkyl;
R11, and R13 are each H or C1-C6 alkyl;
R10 and R12 are independently selected from the group consisting of H, CH3, (C1-C4 alkyl)COOH, (C1-C4 alkyl)NH2, (C1-C4 alkyl)NHC(NH2+)NH2, and CH2(C3—N2 heterocyclic); and
S1 is a bond or a spacer consisting of one to six amino acids, wherein said spacer comprises one or more charged amino acids selected from the group consisting of aspartic acid, glutamic acid, cysteic acid, arginine and lysine, with the proviso that R1 is other than H when R4 is H or C1-C18 alkyl.

### Claim 21 (depends on 20)

The prodrug of claim 20 wherein
R1 is (C1-C6 alkyl)NHR9 or (C1-C6 alkyl)NH—S1—R9;
R2, R4, R11, and R13 are each H;
R5 is NH2;
R8 is H, C1-C8 alkyl, C2-C8 alkenyl, (C1-C4 alkyl)OH, (C1-C4 alkyl)SH, (C2-C3 alkyl)SCH3, (C1-C4 alkyl)CONHH, (C1-C4 alkyl)COOH, (C1-C4 alkyl)NHH, (C1-C4 alkyl)NHC(NH2+)NH2, (C0-C4 alkyl)(C3-C6 cycloalkyl), (C0-C4 alkyl)(C2-C5 heterocyclic), (C0-C4 alkyl)(C6-C10 aryl)R7, (C1-C4 alkyl)(C3-C9 heteroaryl), and C1-C12 alkyl(W1)C1-C12 alkyl, wherein W1 is a heteroatom selected from the group consisting of N, S and O;
R9 is C18-C30 acyl; and
S1 is a spacer consisting of one or two charged amino acids selected from the group consisting of aspartic acid, glutamic acid, cysteic acid, arginine and lysine.

### Claim at position 18

22-24. (canceled)

### Claim 25 (depends on 20)

The prodrug of claim 20, wherein
R2, R4, R8, R11, and R13 are each H;
R1 is (C1-C6 alkyl)NHR9 or (C1-C6 alkyl)NH—S1—R9;
R3 is C2-C8 alkyl;
R5 is NH2; and
R9 is selected from the group consisting of C18-C30 acyl and C18-C30 alkyl; and
S1 is a spacer consisting of one or two charged amino acids selected from the group consisting of aspartic acid, glutamic acid, cysteic acid, arginine and lysine.

### Claim 26 (depends on 25)

The prodrug of claim 25 wherein
R1 is (CH2)4NHR9 or (CH2)4NH—S1—R9;
R3 is C3-C4 alkyl; and
R9 is C18-C28 acyl.

### Claim at position 21

27-30. (canceled)

### Claim 31 (depends on 26)

The prodrug of claim 26 wherein said insulin peptide comprises an A chain sequence of GIVEQCCX8X9ICSLYQLENYCX21-R44 (SEQ ID NO: 73) and a B chain sequence of R22-X25LCGX29X30LVX33X34LYLVCGX41X42GFX45 (SEQ ID NO: 20), wherein
said B chain is linked to said A chain through disulfide linkages;
X8 is histidine or threonine;
X9 is serine, lysine, or alanine;
X21 is alanine, glycine or asparagine;
X25 is histidine or threonine;
X29 is selected from the group consisting of alanine, glycine and serine;
X30 is selected from the group consisting of histidine, aspartic acid, glutamic acid, homocysteic acid and cysteic acid;
X33 is selected from the group consisting of aspartic acid and glutamic acid;
X34 is selected from the group consisting of alanine and threonine;
X41 is selected from the group consisting of glutamic acid, aspartic acid or asparagine;
X42 is selected from the group consisting of alanine, ornithine, lysine and arginine;
X45 is tyrosine or phenylalanine;
R22 is selected from the group consisting of FVNQ (SEQ ID NO: 12), FVKQ (SEQ ID NO: 8), a tripeptide valine-asparagine-glutamine, a dipeptide asparagine-glutamine, glutamine and an N-terminal amine; and
R44 is COOH or CONH2.

### Claim 32 (depends on 31)

The conjugate of claim 31 wherein said A chain comprises a sequence GIVEQCCTSICSLYQLENYCN-R44 (SEQ ID NO: 1) and said B chain comprises a sequence selected from the group consisting of FVNQHLCGSHLVEALYLVCGERGFFYTPKT (SEQ ID NO: 2) FVNQHLCGSHLVEALYLVCGERGFFYTKPT (SEQ ID NO: 9) FVNQHLCGSHLVEALYLVCGERGFFYTDKT (SEQ ID NO: 5) and FVKQHLCGSHLVEALYLVCGERGFFYTEKT (SEQ ID NO: 6).

### Claim 33 (depends on 20)

The prodrug of claim 20, wherein
i) R2 is H and B is selected from the group consisting of glycine(N-methyl), glycine(N-ethyl), glycine(N-propyl), glycine(N-butyl), glycine(N-pentyl), glycine(N-hexyl), glycine(N-heptyl), and glycine(N-octyl) or
ii) R2 and R4 are both H; and R8 is selected from the group consisting of CH3, CH2(C1-C4 alkyl), CH(C1-C4) alkenyl, CH2(C0-C4 alkyl)OH, CH2(C0-C4 alkyl)SH, CH2(C0-C3 alkyl)SCH3, CH2(C0-C3 alkyl)CONH2, CH2(C0-C3 alkyl)COOH, CH2(C0-C4 alkyl)NH2, and CH2(C0-C3 alkyl)NHC(NH2+)NH2; or
iii) R2 is H and B is selected from the group consisting of alanine(N—C1-C6alkyl), leucine(N—C1-C6alkyl), methionine(N—C1-C6alkyl), asparagine(N—C1-C6alkyl), glutamic acid(N—C1-C6alkyl), aspartic acid(N—C1-C6alkyl), glutamine(N—C1-C6alkyl), histidine(N—C1-C6alkyl), lysine(N—C1-C6alkyl), arginine(N—C1-C6alkyl), serine(N—C1-C6alkyl), and cysteine(N—C1-C6alkyl) or
iv) R2, R4 and R8 are independently selected from the group consisting of H and C1-C18 alkyl, or R4 and R8 together with the atoms to which they are attached form a C3-C6 cycloalkyl;
R1 is selected from the group consisting of (C1-C8 alkyl)OR9, (C1-C8 alkyl)SR9, and (C1-C4 alkyl)NHR9; and
R3 is C1-C8 alkyl or R4 and R3 together with the atoms to which they are attached form a 4, 5 or 6 member heterocyclic ring.

### Claim at position 25

34-36. (canceled)

### Claim 37 (depends on 1)

The prodrug of claim 1, wherein A has D-stereochemistry.

### Claim at position 27

38-39. (canceled)

### Claim 40 (depends on 1)

A pharmaceutical composition comprising the prodrug of claim 1, and a pharmaceutically acceptable carrier.

### Claim 41 (depends on 40)

A method of treating hyperglycemia or diabetes, said method comprising administering an effective amount of a pharmaceutical composition of claim 40.

### Claim 42 (depends on 41)

The method of claim 41 wherein the prodrug is administered daily at a fraction, 1/n, of the optimal dosage of the corresponding non-prodrug formulation, wherein n represents the half-life, in days, of the cleavage of A-B-C from Q in serum under physiological conditions.

### Claim 43

(canceled)
